← Home
Bristol Myers Squibb (BMY) stock rocketed Monday after AbbVie’s (ABBV) experimental schizophrenia treatment failed in a pair of midstage studies. The news bolsters Bristol Myers’ new schizophrenia treatment, Cobenfy
+5.36% closed: 2024-11-02
The Drugmaker Hiked Guidance After Sales Beat. stock rose after the pharmaceutical company lifted its 2024 outlook on the back of strong quarterly sales of both legacy and newer drugs, despite generic competition and loss of exclusivity for some of its medicines
Stock Swings
Price Drops
No drop incidentsPrice Hikes
+11.16% closed: 2024-11-13+5.36% closed: 2024-11-02
The Drugmaker Hiked Guidance After Sales Beat. stock rose after the pharmaceutical company lifted its 2024 outlook on the back of strong quarterly sales of both legacy and newer drugs, despite generic competition and loss of exclusivity for some of its medicines
Wait! There's more — sign up for free or log in